As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.
The global pneumonia treatment market stood at a value of around USD 15.8 billion in 2020. The market is further expected to grow at a CAGR of 7.8% in the forecast period of 2022-2027 to attain a value of around USD 24.8 billion by 2026.
Based on product, the vaccines segment is predicted to account for a substantial market share in the pneumonia treatment industry. This increase can be associated with the high cost of drug treatments and the growing drug resistance to many antibiotics. Moreover, with the advent and rapid implementation of pneumococcal vaccinations such as Pneumococcal conjugate vaccine (PCV13) and Pneumococcal polysaccharide vaccine (PPSV23) in the prevention of pneumonia among children below two years of age and adults above 65 years, studies indicate a large fall observed in the incidences of pneumococcal diseases in countries like the United States.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America is expected to occupy a substantial share of the pneumonia treatment industry in the forecast period. This growth can be attributed to the growing awareness of pneumonia in the region. Moreover, with the growing geriatric population in the region, who are more susceptible to such infections, governments in the region are increasingly investing in the healthcare infrastructure to reduce mortality risks associated with pneumonia. Furthermore, a pattern of resistance to existing drugs is being observed in all age groups, which has increased the demand for subsequent research and development in the pneumonia treatments methodologies in order to create an effective cure for this disease, such as vaccines that can work for different kinds of pneumonia. These factors are expected to contribute to the industry growth significantly.
Pneumonia refers to an acute respiratory infection, which inflames the air sacs in one or both lungs. These air sacs or alveoli fill up with fluids like pus, which inflames them, makes breathing painful, and limits oxygen intake. This is accompanied by symptoms like cough, fever, and chills. Pneumonia is caused by a variety of viruses, bacteria, and fungi. In addition, bacterial pneumonia is communicable through airborne droplets of coughs and sneezes. It can also spread through blood. Moreover, the severity of the disease can range from mild to life-threatening. However, pneumonia infection can be prevented through immunisation, sufficient nutrition, and addressing the environmental factors.
By product, the market is divided into:
Among these, drugs can be further bifurcated by type into branded and generic. Out of this, the branded subtype can be further categorised, on the basis of medicine, into quinolones, aminopenicillins, macrolides, B-lactamase inhibitors, cephalosporins, tetracyclines, glycopeptide antibiotics, carbapenems, and others. At the same time, the generic subtype can be further segregated, based on medicine, into quinolones, macrolides, and others.
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
According to the WHO statistics of 2019, pneumonia causes 15% of deaths of all children below five years of age worldwide. This is due to the compromised immune system of children due to malnourishment and undernutrition. In addition, any pre-existing illnesses and environmental factors such as air pollution and passive smoking are also major risk factors. Moreover, with the rapidly ageing population, more people are becoming susceptible to pneumococcal diseases. In this regard, countries worldwide and international organisations are introducing initiatives to control the spread and prevent the risks of pneumonia. For instance, the WHO and UNICEF initiative known as Global Action Plan for Pneumonia and Diarrhoea (GAPPD) aims to prevent, protect, and treat children in collaboration with several countries such as Bangladesh, Uganda, India, and Kenya. Other international institutions include the Gates Foundation, which aims to increase accessibility and the research and development of drugs and treatment through public-private funding schemes. Furthermore, with the advent of the Covid-19 infection, incidences of covid induced pneumonia are on the rise, which is expected to further augment the market growth in the forecast period.
The report gives a detailed analysis of the following key players in the global pneumonia treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
The comprehensive EMR report provides an in-depth assessment of the industry based on the Porter's five forces model and SWOT analysis.
|Scope of the Report||Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Product, Region|
|Breakup by Product||Drugs, Vaccines, Oxygen Therapy|
|Breakup by Region||North America, Europe, Asia Pacific, Latin America, Middle East and Africa|
|Market Dynamics||SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand|
|Competitive Landscape||Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications|
|Companies Covered||Pfizer Inc., Bayer AG, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Lupin Pharmaceuticals, Inc., Others|
|Report Price and Purchase Option||Explore our purchase options that are best suited to your resources and industry needs.|
|Delivery Format||Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.|
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
7 Industry Opportunities and Challenges
8 Global Pneumonia Treatment Market Analysis
8.1 Key Industry Highlights
8.2 Global Pneumonia Treatment Historical Market (2017-2021)
8.3 Global Pneumonia Treatment Market Forecast (2022-2027)
8.4 Global Pneumonia Treatment Market by Product
188.8.131.52 Market Share
184.108.40.206 Historical Trend (2017-2021)
220.127.116.11 Forecast Trend (2022-2027)
18.104.22.168 Breakup by Type
22.214.171.124.1.1 Market Share
126.96.36.199.1.2 Historical Trend (2017-2021)
188.8.131.52.1.3 Forecast Trend (2022-2027)
184.108.40.206.1.4 Breakup by Medicine
220.127.116.11.1.4.4 B-lactamase inhibitors
18.104.22.168.1.4.7 Glycopeptide antibiotics
22.214.171.124.2.1 Market Share
126.96.36.199.2.2 Historical Trend (2017-2021)
188.8.131.52.2.3 Forecast Trend (2022-2027)
184.108.40.206.2.4 Breakup by Medicine
220.127.116.11 Market Share
18.104.22.168 Historical Trend (2017-2021)
22.214.171.124 Forecast Trend (2022-2027)
8.4.3 Oxygen Therapy
126.96.36.199 Market Share
188.8.131.52 Historical Trend (2017-2021)
184.108.40.206 Forecast Trend (2022-2027)
8.5 Global Pneumonia Treatment Market by Region
8.5.1 Market Share
220.127.116.11 North America
18.104.22.168 Asia Pacific
22.214.171.124 Latin America
126.96.36.199 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2017-2021)
9.1.2 Forecast Trend (2022-2027)
9.1.3 Breakup by Country
188.8.131.52 United States of America
9.2.1 Historical Trend (2017-2021)
9.2.2 Forecast Trend (2022-2027)
9.2.3 Breakup by Country
184.108.40.206 United Kingdom
9.3 Asia Pacific
9.3.1 Historical Trend (2017-2021)
9.3.2 Forecast Trend (2022-2027)
9.3.3 Breakup by Country
9.4 Latin America
9.4.1 Historical Trend (2017-2021)
9.4.2 Forecast Trend (2022-2027)
9.4.3 Breakup by Country
9.5 Middle East and Africa
9.5.1 Historical Trend (2017-2021)
9.5.2 Forecast Trend (2022-2027)
9.5.3 Breakup by Country
220.127.116.11 Saudi Arabia
18.104.22.168 United Arab Emirates
22.214.171.124 South Africa
10 Market Dynamics
10.1 SWOT Analysis
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 EMR’s Key Indicators for Demand
10.4 EMR’s Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Company Profiles
12.2.1 Pfizer Inc.
126.96.36.199 Company Overview
188.8.131.52 Product Portfolio
184.108.40.206 Demographic Reach and Achievements
12.2.2 Bayer AG
220.127.116.11 Company Overview
18.104.22.168 Product Portfolio
22.214.171.124 Demographic Reach and Achievements
12.2.3 Abbott Laboratories
126.96.36.199 Company Overview
188.8.131.52 Product Portfolio
184.108.40.206 Demographic Reach and Achievements
12.2.4 Novartis AG
220.127.116.11 Company Overview
18.104.22.168 Product Portfolio
22.214.171.124 Demographic Reach and Achievements
12.2.5 GlaxoSmithKline plc
126.96.36.199 Company Overview
188.8.131.52 Product Portfolio
184.108.40.206 Demographic Reach and Achievements
12.2.6 Lupin Pharmaceuticals, Inc.
220.127.116.11 Company Overview
18.104.22.168 Product Portfolio
22.214.171.124 Demographic Reach and Achievements
13 Industry Events and Developments
List of Figures and Tables
1. Global Pneumonia Treatment Market: Key Industry Highlights, 2016 and 2026
2. Global Pneumonia Treatment Historical Market: Breakup by Product (USD Billion), 2017-2021
3. Global Pneumonia Treatment Market Forecast: Breakup by Product (USD Billion), 2022-2027
4. Global Pneumonia Treatment Historical Market: Breakup by Region (USD Billion), 2017-2021
5. Global Pneumonia Treatment Market Forecast: Breakup by Region (USD Billion), 2022-2027
6. North America Pneumonia Treatment Historical Market: Breakup by Country (USD Billion), 2017-2021
7. North America Pneumonia Treatment Market Forecast: Breakup by Country (USD Billion), 2022-2027
8. Europe Pneumonia Treatment Historical Market: Breakup by Country (USD Billion), 2017-2021
9. Europe Pneumonia Treatment Market Forecast: Breakup by Country (USD Billion), 2022-2027
10. Asia Pacific Pneumonia Treatment Historical Market: Breakup by Country (USD Billion), 2017-2021
11. Asia Pacific Pneumonia Treatment Market Forecast: Breakup by Country (USD Billion), 2022-2027
12. Latin America Pneumonia Treatment Historical Market: Breakup by Country (USD Billion), 2017-2021
13. Latin America Pneumonia Treatment Market Forecast: Breakup by Country (USD Billion), 2022-2027
14. Middle East and Africa Pneumonia Treatment Historical Market: Breakup by Country (USD Billion), 2017-2021
15. Middle East and Africa Pneumonia Treatment Market Forecast: Breakup by Country (USD Billion), 2022-2027
16. Global Pneumonia Treatment Market Structure
In 2020, the global pneumonia treatment market attained a value of nearly USD 15.8 billion.
The market is projected to grow at a CAGR of 7.8% between 2021 and 2026.
The market is estimated to witness a healthy growth in the forecast period of 2022-2027 to reach USD 24.8 billion by 2026.
The major drivers of the industry, such as the increased mortality risks of pneumonia among children below 5, growing geriatric population susceptible to pneumonic infections, heightened demand for pneumonia treatment such as vaccines and medicines, and the rapid investments being made by the governments and key market players in the manufacturing of vaccines due to the rising drug resistance, are expected to aid the market growth.
The key market trends guiding the growth of the industry include the increased investments in the research and development of pneumonia treatment by international organisations.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The significant product segments include drugs, vaccines, and oxygen therapy. Among these, drugs can be further divided by type into branded and generic. While the branded subtype can be further categorised into quinolones, aminopenicillins, macrolides, B-lactamase inhibitors, cephalosporins, tetracyclines, glycopeptide antibiotics, carbapenems, and others, the generic subtype can be further segregated into quinolones, macrolides, and others based on medicine.
The major players in the industry are Pfizer Inc, Bayer AG, Abbott Laboratories, Novartis AG, GlaxoSmithKline Plc, Lupin Pharmaceuticals Inc., and others.
The global pneumonia treatment market attained a value of USD 15.8 billion in 2020, driven by the growing incidences of pneumonia globally. Aided by the rapidly spreading pneumonia caused by Covid-19, the market is expected to witness a further growth in the forecast period of 2022-2027, growing at a CAGR of 7.8. The market is projected to reach USD 24.8 billion by 2026.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. By product, the market can be segmented into drugs, vaccines, and oxygen therapy. Among these, drugs can be further divided by type into branded and generic, out of which, the branded subtype has been further categorised, on the basis of medicine, into quinolones, aminopenicillins, macrolides, B-lactamase inhibitors, cephalosporins, tetracyclines, glycopeptide antibiotics, carbapenems and others. Meanwhile, the generic subtype has been further segregated, based on medicine, into quinolones, macrolides, and others. The major regional markets for pneumonia treatment are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Pfizer Inc, Bayer AG, Abbott Laboratories, Novartis AG, GlaxoSmithKline Plc, and Lupin Pharmaceuticals Inc., among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.